---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-01-18T20:46:54.631769'
end_time: '2026-01-18T20:52:15.559855'
duration_seconds: 320.93
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: SIRT1
  gene_symbol: SIRT1
  uniprot_accession: Q96EB6
  protein_description: 'RecName: Full=NAD-dependent protein deacetylase sirtuin-1
    {ECO:0000305}; Short=hSIRT1; EC=2.3.1.286 {ECO:0000255|PROSITE-ProRule:PRU00236,
    ECO:0000269|PubMed:12006491, ECO:0000269|PubMed:22918831, ECO:0000269|PubMed:30409912,
    ECO:0000269|PubMed:32034146}; AltName: Full=NAD-dependent protein deacylase sirtuin-1
    {ECO:0000305}; EC=2.3.1.- {ECO:0000269|PubMed:28497810}; AltName: Full=Regulatory
    protein SIR2 homolog 1; AltName: Full=SIR2-like protein 1; Short=hSIR2; Contains:
    RecName: Full=SirtT1 75 kDa fragment {ECO:0000303|PubMed:21987377}; Short=75SirT1
    {ECO:0000303|PubMed:21987377};'
  gene_info: Name=SIRT1 {ECO:0000303|PubMed:12535671, ECO:0000312|HGNC:HGNC:14929};
    Synonyms=SIR2L1;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the sirtuin family. Class I subfamily.
  protein_domains: DHS-like_NAD/FAD-binding_dom. (IPR029035); NAD-dep_sirtuin_deacylases.
    (IPR050134); Sirtuin. (IPR003000); Sirtuin_cat_small_dom_sf. (IPR026591); Ssirtuin_cat_dom.
    (IPR026590)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 12
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q96EB6
- **Protein Description:** RecName: Full=NAD-dependent protein deacetylase sirtuin-1 {ECO:0000305}; Short=hSIRT1; EC=2.3.1.286 {ECO:0000255|PROSITE-ProRule:PRU00236, ECO:0000269|PubMed:12006491, ECO:0000269|PubMed:22918831, ECO:0000269|PubMed:30409912, ECO:0000269|PubMed:32034146}; AltName: Full=NAD-dependent protein deacylase sirtuin-1 {ECO:0000305}; EC=2.3.1.- {ECO:0000269|PubMed:28497810}; AltName: Full=Regulatory protein SIR2 homolog 1; AltName: Full=SIR2-like protein 1; Short=hSIR2; Contains: RecName: Full=SirtT1 75 kDa fragment {ECO:0000303|PubMed:21987377}; Short=75SirT1 {ECO:0000303|PubMed:21987377};
- **Gene Information:** Name=SIRT1 {ECO:0000303|PubMed:12535671, ECO:0000312|HGNC:HGNC:14929}; Synonyms=SIR2L1;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the sirtuin family. Class I subfamily.
- **Key Domains:** DHS-like_NAD/FAD-binding_dom. (IPR029035); NAD-dep_sirtuin_deacylases. (IPR050134); Sirtuin. (IPR003000); Sirtuin_cat_small_dom_sf. (IPR026591); Ssirtuin_cat_dom. (IPR026590)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "SIRT1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'SIRT1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **SIRT1** (gene ID: SIRT1, UniProt: Q96EB6) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q96EB6
- **Protein Description:** RecName: Full=NAD-dependent protein deacetylase sirtuin-1 {ECO:0000305}; Short=hSIRT1; EC=2.3.1.286 {ECO:0000255|PROSITE-ProRule:PRU00236, ECO:0000269|PubMed:12006491, ECO:0000269|PubMed:22918831, ECO:0000269|PubMed:30409912, ECO:0000269|PubMed:32034146}; AltName: Full=NAD-dependent protein deacylase sirtuin-1 {ECO:0000305}; EC=2.3.1.- {ECO:0000269|PubMed:28497810}; AltName: Full=Regulatory protein SIR2 homolog 1; AltName: Full=SIR2-like protein 1; Short=hSIR2; Contains: RecName: Full=SirtT1 75 kDa fragment {ECO:0000303|PubMed:21987377}; Short=75SirT1 {ECO:0000303|PubMed:21987377};
- **Gene Information:** Name=SIRT1 {ECO:0000303|PubMed:12535671, ECO:0000312|HGNC:HGNC:14929}; Synonyms=SIR2L1;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the sirtuin family. Class I subfamily.
- **Key Domains:** DHS-like_NAD/FAD-binding_dom. (IPR029035); NAD-dep_sirtuin_deacylases. (IPR050134); Sirtuin. (IPR003000); Sirtuin_cat_small_dom_sf. (IPR026591); Ssirtuin_cat_dom. (IPR026590)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "SIRT1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'SIRT1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **SIRT1** (gene ID: SIRT1, UniProt: Q96EB6) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan overview and verification
We verified the target as human SIRT1 (gene SIRT1; UniProt Q96EB6), a Class I sirtuin with a conserved Rossmann-like NAD-binding catalytic core and zinc-finger motif. The gene symbol, organism (Homo sapiens), and domain family match UniProt and recent reviews (including an endothelial-focused 2024 update) (campagna2024themultifacetedrole pages 1-2, campagna2024themultifacetedrole pages 2-3).

Key concepts and definitions with current understanding
- Identity and enzyme class: SIRT1 is an NAD+-dependent lysine deacetylase/deacylase. It couples lysine acyl removal to NAD+ cleavage, producing nicotinamide and 2′-O-acetyl-ADP-ribose (EC 2.3.1.286). Sirtuins share a conserved catalytic mechanism centered on an NAD-binding Rossmann-like fold and a catalytic histidine that facilitates the reaction chemistry (Castiello 2025 review) (castiello2025newfrontiersfor pages 67-70). SIRT1 deacetylates both histone and non‑histone substrates and is a key metabolic and stress-response regulator (Campagna et al., Cells, 2024; Bursch et al., Molecules, 2024) (campagna2024themultifacetedrole pages 1-2, bursch2024currenttrendsin pages 6-7). URLs: https://doi.org/10.3390/cells13171469 (Sep 2024); https://doi.org/10.3390/molecules29051185 (Mar 2024).
- Substrate scope: Histones include H4K16 (preferentially) and H3K9/H3K14/H4K8/H4K12. Non‑histone substrates include p53 (notably K382), NF‑κB p65/RelA, FOXO factors, HIF1α/HIF2α, and PGC‑1α. These deacetylation events modulate apoptosis, chromatin state, inflammation, hypoxia responses, and mitochondrial biogenesis (Campagna 2024; Castiello 2025) (campagna2024themultifacetedrole pages 1-2, castiello2025newfrontiersfor pages 67-70, castiello2025newfrontiersfor pages 77-79).

Recent developments and latest research (prioritize 2023–2024)
- Mechanism and allosteric activation: Contemporary analyses emphasize that small‑molecule SIRT1-activating compounds (STACs) function allosterically by lowering the Km for certain peptide substrates in a substrate‑sequence‑dependent manner, with a defined STAC-binding region and sensitivity to mutations such as E230K. This preserves NAD+ dependence and supports the canonical deacetylation chemistry (Bursch et al., 2024, Molecules; review of mechanism and kinetic behavior) (bursch2024currenttrendsin pages 6-7). URL: https://doi.org/10.3390/molecules29051185 (Mar 2024).
- Post‑translational regulation and localization: A 2024 endothelial review summarizes emerging details on SIRT1 regulation by phosphorylation (e.g., CDK5, HIPK2, JAK1), SUMOylation (Lys734), ubiquitination (e.g., SMURF2), S‑nitrosylation (Cys387/Cys390), O‑GlcNAcylation (Ser549), and other redox modifications, which together tune localization, stability, and activity. This work also highlights the connection between NAD+ biosynthesis pathways and endothelial aging (Campagna et al., Cells, 2024) (campagna2024themultifacetedrole pages 2-3, campagna2024themultifacetedrole pages 1-2). URL: https://doi.org/10.3390/cells13171469 (Sep 2024).

Primary function, reaction, and substrate specificity
- Catalyzed reaction: SIRT1 is a lysine deacetylase/deacylase that uses NAD+ to remove acetyl (and certain acyl) groups from ε‑lysines, yielding deacetylated protein, nicotinamide, and 2′‑O‑acetyl‑ADP‑ribose (Castiello 2025) (castiello2025newfrontiersfor pages 67-70).
- Substrate specificity and kinetics: SIRT1 targets specific histone lysines (e.g., H4K16ac) and many non‑histone proteins. STACs exhibit substrate‑sequence dependence, activating deacetylation preferentially on peptides with certain C‑terminal aromatic/hydrophobic residues; this is consistent with direct activation of SIRT1 rather than altered NAD+ affinity (Bursch 2024) (bursch2024currenttrendsin pages 6-7).
- Exemplar substrates: p53 K382 deacetylation attenuates p53 transcriptional activity and influences apoptosis; SIRT1 deacetylates FOXO family members to adjust stress responses; deacetylation of NF‑κB p65 dampens inflammatory transcription; SIRT1 deacetylation of HIF1α/HIF2α modulates hypoxia signaling; and deacetylation of PGC‑1α promotes mitochondrial biogenesis and oxidative metabolism (Campagna 2024; Castiello 2025) (campagna2024themultifacetedrole pages 1-2, castiello2025newfrontiersfor pages 67-70, castiello2025newfrontiersfor pages 77-79).

Subcellular localization and regulation
- Localization: SIRT1 is predominantly nuclear but undergoes regulated nucleo‑cytoplasmic shuttling; it contains an N‑terminal nuclear localization signal and can exhibit nuclear vs cytoplasmic distribution depending on cell type and context (Campagna 2024; Castiello 2025) (campagna2024themultifacetedrole pages 1-2, castiello2025newfrontiersfor pages 60-63). Nuclear enrichment is typical in endothelium and cardiomyocytes, with context‑dependent cytoplasmic pools described. Localization and activity are controlled by PTMs and cellular NAD+ availability (Campagna 2024) (campagna2024themultifacetedrole pages 2-3, campagna2024themultifacetedrole pages 1-2).

Mechanistic pathway roles and precise nodes
- DNA damage and chromatin regulation: SIRT1 deacetylates p53 and Ku70, modulating apoptosis and DNA repair, and promotes heterochromatin formation via histone deacetylation (e.g., H4K16ac) (Castiello 2025; Campagna 2024) (castiello2025newfrontiersfor pages 67-70, campagna2024themultifacetedrole pages 1-2).
- Metabolism and mitochondrial biogenesis: SIRT1 deacetylates PGC‑1α, advancing oxidative metabolism and mitochondrial biogenesis (Campagna 2024; Castiello 2025) (campagna2024themultifacetedrole pages 1-2, castiello2025newfrontiersfor pages 67-70).
- Inflammation: SIRT1 deacetylates NF‑κB p65/RelA, thereby repressing pro‑inflammatory transcription. Through this node, SIRT1 is positioned as an anti‑inflammatory regulator in multiple tissues (Castiello 2025; Campagna 2024) (castiello2025newfrontiersfor pages 77-79, campagna2024themultifacetedrole pages 1-2).
- Hypoxia signaling: Deacetylation of HIF1α/HIF2α modulates hypoxia responses in endothelial and other contexts (Castiello 2025) (castiello2025newfrontiersfor pages 77-79).
- Cardiovascular context: Reviews highlight SIRT1 roles in endothelial function, oxidative stress control, senescence, and atherosclerosis progression. In the cardiovascular system, SIRT1’s dynamic localization and regulation are emphasized as central to its protective actions (Dinislam 2026; Campagna 2024) (dinislam2026sirt1thefirst pages 1-3, campagna2024themultifacetedrole pages 1-2). URL: https://doi.org/10.3389/fphar.2025.1668718 (Jan 2026); https://doi.org/10.3390/cells13171469 (Sep 2024).

Pharmacologic modulators, selectivity, and clinical/translational notes (2023–2024 emphasis)
- Natural and synthetic activators: Resveratrol is the prototype natural STAC, though direct activation mechanisms have been debated; synthetic STACs (SRT1720, SRT2104, SRT1460, SRT2183) show potent SIRT1‑dependent activity in vitro and in cells, often lowering Km for specific peptide substrates; substrate sequence near the acetyl‑lysine is critical, and E230K mutation attenuates STAC activation without affecting basal kinetics (Bursch 2024) (bursch2024currenttrendsin pages 6-7). URL: https://doi.org/10.3390/molecules29051185 (Mar 2024).
- NAD+ boosters: Modulating NAD+ via precursors (e.g., NR, NAM) can influence SIRT1 activity, with translational interest in metabolic and vascular applications (Campagna 2024; Bursch 2024) (campagna2024themultifacetedrole pages 1-2, bursch2024currenttrendsin pages 6-7).
- Clinical observations: SRT2104 advanced to human testing with general tolerability but poor oral bioavailability reported; in short studies, lipid profile improvements were observed (lower cholesterol and triglycerides; increased HDL/LDL ratio) (Bursch 2024) (bursch2024currenttrendsin pages 6-7). Resveratrol has been tested clinically with mixed efficacy, reflecting bioavailability and target‑engagement challenges (Bursch 2024) (bursch2024currenttrendsin pages 6-7).

Current applications and implementations
- Vascular aging and endothelium: Mechanistic and translational efforts are focused on boosting SIRT1 activity to counter endothelial senescence and vascular dysfunction, integrating NAD+ metabolism and PTM control of SIRT1 (Campagna 2024) (campagna2024themultifacetedrole pages 1-2, campagna2024themultifacetedrole pages 2-3).
- Broader cardiometabolic context: Reviews underscore SIRT1 involvement across endothelial function, oxidative stress, inflammation, and senescence in cardiovascular disease, supporting continued development of SIRT1 modulators (Dinislam 2026) (dinislam2026sirt1thefirst pages 1-3).

Expert opinions and analysis from authoritative sources
- Endothelial SIRT1: The 2024 Cells review synthesizes mechanistic regulation (PTMs, NAD+ pathways), histone and non‑histone substrate actions, and therapeutic angles for vascular aging, emphasizing the need for precise modulation of SIRT1 activity and localization (Campagna et al., 2024) (campagna2024themultifacetedrole pages 1-2, campagna2024themultifacetedrole pages 2-3).
- Sirtuin modulation landscape: The 2024 Molecules review highlights lessons from STACs—substrate‑sequence dependence, defined binding determinants, the E230K sensitivity, and translational bottlenecks (bioavailability/off‑targets)—guiding next‑generation SIRT1 modulators (Bursch et al., 2024) (bursch2024currenttrendsin pages 6-7).

Relevant statistics and data from recent studies
- STAC selectivity and kinetics: STACs were reported to confer large fold‑increases in apparent SIRT1 activity on compatible peptide substrates (and selectivity over SIRT2/3) in biochemical assays; these effects associate with reduced Km for acetyl‑lysine without altering the Km for NAD+ (Bursch 2024) (bursch2024currenttrendsin pages 6-7).
- Translational lipid effects: In short clinical investigations summarized in 2024, SRT2104 lowered total cholesterol and triglycerides and raised the HDL/LDL ratio but suffered from poor oral bioavailability, underscoring the medicinal chemistry gap to clinical efficacy (Bursch 2024) (bursch2024currenttrendsin pages 6-7).

Concise functional summary table
| Category | Key facts | Primary recent sources |
|---|---|---|
| Identity & domains | - Human SIRT1 (UniProt Q96EB6), ~747 aa<br>- Class I sirtuin; NAD+-dependent deacetylase with Rossmann-like NAD-binding fold and zinc-finger motif | Campagna et al., Cells 2024 — https://doi.org/10.3390/cells13171469 (campagna2024themultifacetedrole pages 1-2) |
| Enzymatic reaction & mechanism | - NAD+-dependent deacetylation (EC 2.3.1.286): yields nicotinamide + 2'-O-acetyl-ADP-ribose<br>- Conserved mechanism: NAD+ binding (Rossmann fold), catalytic His-mediated chemistry<br>- Allosteric STACs lower Km for acyl-lysine substrates (substrate-sequence dependence) | Castiello 2025 — URL not provided (castiello2025newfrontiersfor pages 67-70); Bursch et al., Molecules 2024 — https://doi.org/10.3390/molecules29051185 (bursch2024currenttrendsin pages 6-7) |
| Exemplary substrates (histone & non-histone) | - Histone: preferentially deacetylates H4K16ac (also H3K9/K14)<br>- Non-histone: p53 (K382) deacetylation; FOXO1/3; NF-κB RelA/p65; HIF1α/2α; PGC-1α (mitochondrial regulator) | Campagna et al., Cells 2024 — https://doi.org/10.3390/cells13171469 (campagna2024themultifacetedrole pages 1-2); Castiello 2025 — URL not provided (castiello2025newfrontiersfor pages 67-70) |
| Subcellular localization & regulation | - Predominantly nuclear with regulated nucleo–cytoplasmic shuttling; NLS around aa41–46 reported<br>- Localization/activity modulated by PTMs (phosphorylation, SUMOylation, ubiquitination, S‑nitrosylation, O‑GlcNAcylation) and NAD+ availability<br>- Interacting partners and stress context alter localization/stability | Campagna et al., Cells 2024 — https://doi.org/10.3390/cells13171469 (campagna2024themultifacetedrole pages 2-3, campagna2024themultifacetedrole pages 1-2) |
| Pathway nodes (mechanistic roles) | - DNA damage response: deacetylates p53, Ku70 → modulates apoptosis/repair<br>- Chromatin regulation: H4K16 deacetylation → heterochromatin/transcriptional repression<br>- Metabolism: deacetylates PGC‑1α → promotes mitochondrial biogenesis/oxidative metabolism<br>- Circadian: deacetylates core clock components (BMAL1/PER2) to tune rhythms<br>- Inflammation: deacetylates NF‑κB RelA/p65 and suppresses NLRP3-driven inflammation | Castiello 2025 — URL not provided (castiello2025newfrontiersfor pages 67-70, castiello2025newfrontiersfor pages 77-79); Campagna et al., Cells 2024 — https://doi.org/10.3390/cells13171469 (campagna2024themultifacetedrole pages 1-2) |
| Pharmacologic modulators | - Resveratrol: natural STAC; direct SIRT1 activation contested in mechanism studies<br>- Synthetic STACs (SRT1720, SRT2104): allosteric activation, substrate-sequence dependence; E230K mutation reduces STAC activation in mechanistic studies<br>- NAD+ boosters (nicotinamide riboside, NAM): increase NAD+ to support SIRT1 activity | Bursch et al., Molecules 2024 — https://doi.org/10.3390/molecules29051185 (bursch2024currenttrendsin pages 6-7); Dinislam et al., Frontiers in Pharmacology 2026 — https://doi.org/10.3389/fphar.2025.1668718 (dinislam2026sirt1thefirst pages 1-3) |
| Clinical / translational notes | - SRT2104 progressed to human testing: generally tolerated but reported poor oral bioavailability; small lipid-profile benefits observed in short studies<br>- Resveratrol tested in multiple trials with mixed outcomes; translational efficacy variable<br>- NAD+ precursor trials ongoing with context-dependent results | Bursch et al., Molecules 2024 — https://doi.org/10.3390/molecules29051185 (bursch2024currenttrendsin pages 6-7); Dinislam et al., Frontiers in Pharmacology 2026 — https://doi.org/10.3389/fphar.2025.1668718 (dinislam2026sirt1thefirst pages 1-3) |
| Expert reviews | - Vascular aging: Campagna et al., Cells 2024 — comprehensive endothelial SIRT1 review<br>- Sirtuin modulators: Bursch et al., Molecules 2024 — review of activator/inhibitor development<br>- Broad epigenetics & pathway context: Castiello 2025 — general review | Campagna et al., Cells 2024 — https://doi.org/10.3390/cells13171469 (campagna2024themultifacetedrole pages 1-2); Bursch et al., Molecules 2024 — https://doi.org/10.3390/molecules29051185 (bursch2024currenttrendsin pages 6-7); Castiello 2025 — URL not provided (castiello2025newfrontiersfor pages 60-63) |


*Table: Compact functional summary table for human SIRT1 (UniProt Q96EB6) showing core identity, mechanism, substrates, localization/regulation, pathway roles, modulators, clinical notes and key recent sources (2023–2024). Useful as a quick reference for mechanistic annotation and literature starting points.*

Conclusion
Human SIRT1 (Q96EB6) is a nuclear‑biased, NAD+-dependent deacetylase that orchestrates genome regulation, stress responses, and metabolism through precise deacetylation of histones (e.g., H4K16) and non‑histone factors (p53, NF‑κB p65, FOXOs, HIFs, PGC‑1α). Recent work refines the allosteric activation model of SIRT1 by STACs, revealing stringent substrate‑sequence requirements and explaining variable outcomes across assays and trials. 2023–2024 reviews emphasize PTM‑dependent control of SIRT1 activity and localization, integration with NAD+ biosynthesis, and translational opportunities in vascular aging and cardiometabolism. Future clinical success likely hinges on improving bioavailability and target engagement while leveraging context‑specific substrate preference and subcellular localization to achieve pathway‑precise modulation (Campagna 2024; Bursch 2024; Castiello 2025; Dinislam 2026) (campagna2024themultifacetedrole pages 1-2, campagna2024themultifacetedrole pages 2-3, bursch2024currenttrendsin pages 6-7, castiello2025newfrontiersfor pages 67-70, castiello2025newfrontiersfor pages 77-79, dinislam2026sirt1thefirst pages 1-3).

References

1. (campagna2024themultifacetedrole pages 1-2): Roberto Campagna, Laura Mazzanti, Veronica Pompei, Sonila Alia, Arianna Vignini, and Monica Emanuelli. The multifaceted role of endothelial sirt1 in vascular aging: an update. Cells, 13:1469, Sep 2024. URL: https://doi.org/10.3390/cells13171469, doi:10.3390/cells13171469. This article has 32 citations and is from a poor quality or predatory journal.

2. (campagna2024themultifacetedrole pages 2-3): Roberto Campagna, Laura Mazzanti, Veronica Pompei, Sonila Alia, Arianna Vignini, and Monica Emanuelli. The multifaceted role of endothelial sirt1 in vascular aging: an update. Cells, 13:1469, Sep 2024. URL: https://doi.org/10.3390/cells13171469, doi:10.3390/cells13171469. This article has 32 citations and is from a poor quality or predatory journal.

3. (castiello2025newfrontiersfor pages 67-70): C Castiello. New frontiers for epigenetics: from immunology to cardiovascular diseases and beyond. Unknown journal, 2025.

4. (bursch2024currenttrendsin pages 6-7): Karina L. Bursch, Christopher J. Goetz, and Brian C. Smith. Current trends in sirtuin activator and inhibitor development. Molecules, 29:1185, Mar 2024. URL: https://doi.org/10.3390/molecules29051185, doi:10.3390/molecules29051185. This article has 34 citations and is from a poor quality or predatory journal.

5. (castiello2025newfrontiersfor pages 77-79): C Castiello. New frontiers for epigenetics: from immunology to cardiovascular diseases and beyond. Unknown journal, 2025.

6. (castiello2025newfrontiersfor pages 60-63): C Castiello. New frontiers for epigenetics: from immunology to cardiovascular diseases and beyond. Unknown journal, 2025.

7. (dinislam2026sirt1thefirst pages 1-3): Khuzin Dinislam, Muneer Ahmed Khoso, Valeriy A. Kataev, Svetlana Meshcheryakova, Heng Liu, Ling Liu, Madi Guo, Song Wang, Han Lou, Yong Zhang, and Xin Liu. Sirt1: the first key to unlocking the mystery of cardiovascular diseases. Frontiers in Pharmacology, Jan 2026. URL: https://doi.org/10.3389/fphar.2025.1668718, doi:10.3389/fphar.2025.1668718. This article has 0 citations and is from a poor quality or predatory journal.

## Citations

1. castiello2025newfrontiersfor pages 67-70
2. bursch2024currenttrendsin pages 6-7
3. castiello2025newfrontiersfor pages 77-79
4. campagna2024themultifacetedrole pages 1-2
5. castiello2025newfrontiersfor pages 60-63
6. campagna2024themultifacetedrole pages 2-3
7. https://doi.org/10.3390/cells13171469
8. https://doi.org/10.3390/molecules29051185
9. https://doi.org/10.3389/fphar.2025.1668718
10. https://doi.org/10.3390/cells13171469,
11. https://doi.org/10.3390/molecules29051185,
12. https://doi.org/10.3389/fphar.2025.1668718,